List of Excipients in Branded Drug RETROVIR

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ViiV Healthcare Company	RETROVIR	zidovudine	49702-211	CELLULOSE, MICROCRYSTALLINE
ViiV Healthcare Company	RETROVIR	zidovudine	49702-211	DIMETHICONE
ViiV Healthcare Company	RETROVIR	zidovudine	49702-211	FERROSOFERRIC OXIDE
ViiV Healthcare Company	RETROVIR	zidovudine	49702-211	GELATIN

Retrovir Excipient Strategy and Commercial Opportunities for Zidovudine

Last updated: September 9, 2026

Retrovir is the original brand of zidovudine, a small-molecule nucleoside reverse transcriptase inhibitor approved by the FDA in 1987. Its core composition, active-ingredient, and original method-of-use exclusivity have expired. The commercial opportunity is therefore not a brand-based patent position. It is in low-cost generic supply, pediatric delivery, taste-masked oral liquids, combination products, hospital injections, and differentiated formulations with measurable adherence or manufacturing advantages.

Retrovir’s principal dosage forms are capsules, oral solution, and intravenous infusion. The key excipient constraints are zidovudine’s bitterness, pediatric dosing requirements, syrup stability, preservative selection, injection compatibility, and the need to avoid unnecessary formulation complexity.

What is Retrovir and which active ingredient does it contain?

Retrovir contains zidovudine, also known as azidothymidine or AZT. Zidovudine inhibits HIV reverse transcriptase after intracellular conversion to its active triphosphate metabolite. It was initially used as monotherapy and is now generally administered as part of combination antiretroviral therapy.

Attribute	Retrovir
Active ingredient	Zidovudine
Drug class	Nucleoside reverse transcriptase inhibitor
Original sponsor	Burroughs Wellcome
Current corporate ownership context	GSK and ViiV Healthcare legacy HIV portfolio
First FDA approval	1987
Main dosage forms	Capsules, oral solution, intravenous injection
Common capsule strengths	100 mg and 200 mg
Oral solution strength	10 mg/mL
Injection strength	10 mg/mL
Biosimilar pathway	Not applicable
Primary regulatory pathway for competitors	Abbreviated New Drug Application
Core patent position	Expired in the United States

The FDA approved zidovudine before the modern Hatch-Waxman framework matured. Its original commercial protection has therefore been exhausted, leaving formulation execution, supply reliability, and market access as the main competitive variables. [1,2]

What excipients are used in Retrovir formulations?

Retrovir uses different excipient systems for solid oral, liquid oral, and intravenous products. The precise inactive-ingredient profile varies by dosage form and jurisdiction.

Retrovir capsules

The capsule formulation uses conventional excipients for powder flow, tablet or capsule fill uniformity, disintegration, and shell integrity. Reported capsule excipients include corn starch, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate. The capsule shell contains gelatin and colorants, with titanium dioxide used in certain presentations. [2]

These materials are low-cost and widely available. Their commercial value is limited because they are standard excipients with extensive prior art and little ability to create a durable patent moat.

The main development considerations are:

• uniform low-dose fill performance;
• prevention of segregation in capsule blends;
• control of dissolution after long-term storage;
• avoidance of excessive lubricant levels;
• supply qualification for gelatin and colorants;
• compatibility with global dietary and labeling requirements.

A generic capsule manufacturer can usually obtain a low-cost formulation using conventional wet granulation, dry granulation, or direct-blend processing, subject to bioequivalence and quality requirements.

Retrovir oral solution

Retrovir oral solution is a 10 mg/mL liquid formulation intended for patients who cannot swallow capsules and for pediatric dosing. The formulation uses a high-solubility approach rather than a suspension strategy. Reported excipients include sucrose, glycerin, sodium citrate, citric acid, flavoring agents, methylparaben, propylparaben, and purified water. [2]

The liquid presents the strongest excipient-driven commercial opportunity because zidovudine has a pronounced bitter taste and pediatric patients require flexible dosing.

The critical formulation attributes are:

• reliable zidovudine solubility across the labeled shelf-life;
• taste masking without excessive sweetness;
• preservative effectiveness;
• pH control;
• microbial robustness after opening;
• accurate dosing with an oral syringe;
• low viscosity sufficient for accurate measurement;
• compatibility with common administration devices.

Sucrose-based systems provide palatability but create concerns for patients with metabolic disorders and may increase formulation weight and shipping cost. A sugar-free formulation using sorbitol, glycerol, maltitol, or another polyol could create a product differentiation opportunity, although gastrointestinal tolerability and osmolality must be controlled.

Taste-masking technologies such as ion-exchange resins, cyclodextrin complexes, polymeric coatings, and lipid-based systems could support a new pediatric product. The commercial benefit would depend on whether the improved taste produces measurable adherence or reduces administration problems. A reformulation that only changes flavor is unlikely to support meaningful pricing unless it obtains a regulatory advantage or wins institutional contracts.

Retrovir intravenous formulation

The intravenous product contains zidovudine at 10 mg/mL in an aqueous formulation. The label identifies water for injection and pH-adjusting agents, with sodium hydroxide and hydrochloric acid used to establish the required pH. Sodium chloride may be present for tonicity and product compatibility. [2]

The injection opportunity is narrower than the oral opportunity. Hospitals may use intravenous zidovudine in specific clinical circumstances, including perinatal or occupational exposure protocols, although contemporary antiretroviral practice has reduced the role of zidovudine monotherapy.

The main technical risks are:

• precipitation during dilution;
• adsorption to infusion materials;
• particulate formation;
• container-closure compatibility;
• sterility assurance;
• stability after dilution;
• low-volume dosing accuracy.

A ready-to-use premixed bag, low-waste vial, or pharmacy-friendly concentrate could compete on handling and procurement efficiency. Such products would need to justify the added manufacturing and regulatory burden against a limited market.

What formulation patents protect Retrovir?

No commercially meaningful composition-of-matter exclusivity remains for zidovudine in the United States. The original patent estate covered zidovudine and related antiviral uses, but those rights expired years ago. The brand’s commercial protection cannot be recreated through routine use of conventional excipients.

Potentially relevant secondary patent categories include:

1. taste-masked zidovudine compositions;
2. sustained-release oral dosage forms;
3. pediatric liquid formulations;
4. fixed-dose combinations;
5. specific crystalline or polymorphic forms;
6. manufacturing processes;
7. container-closure systems;
8. dosing methods for specific patient populations.

A new patent would need to claim a genuinely non-obvious technical solution. A simple substitution of sucrose with another sweetener, or replacement of one preservative with another, would face significant obviousness risk unless supported by unexpected stability, palatability, bioavailability, or manufacturing data.

How strong is the current Retrovir patent estate?

Patent category	Current commercial position
Zidovudine composition of matter	Expired
Basic oral dosage forms	Expired or commercially unprotective
Conventional capsule excipients	Weak patent opportunity
Conventional oral-solution excipients	Weak unless linked to unexpected performance
Pediatric taste masking	Potentially protectable if technically differentiated
Sustained-release delivery	Potentially protectable but commercially uncertain
Fixed-dose combinations	Product- and jurisdiction-specific
Manufacturing process	Potentially protectable, usually narrow
Brand trademark	Separate from drug exclusivity and does not block generics

The best patent strategy is a narrow formulation estate around a measurable product advantage. Relevant claim themes would include a defined dissolution profile, long-term chemical stability, reduced bitterness, improved dose accuracy, reduced preservative load, or a specific delivery device.

When does Retrovir lose exclusivity?

Retrovir lost its meaningful U.S. exclusivity long ago. The product’s original FDA approval dates from 1987, and zidovudine generic competition has existed for many years. There is no current small-molecule data exclusivity period capable of delaying an ANDA entrant.

Exclusivity type	Retrovir status
New chemical entity exclusivity	Expired
Pediatric exclusivity	Historical and expired
Orphan exclusivity	Not the principal commercial barrier
New formulation exclusivity	No broad current barrier identified
Patent-based exclusivity	Original protection expired
Biosimilar exclusivity	Not applicable
Generic approval route	ANDA

The relevant commercial question is not when Retrovir loses exclusivity. It is whether a new zidovudine formulation can obtain its own regulatory exclusivity or enforceable formulation patents. A 505(b)(2) product could be relevant where the formulation, route, dosage form, or clinical use differs materially from an approved reference product. The pathway would not restore protection to ordinary zidovudine capsules.

What is the FDA regulatory status of Retrovir?

Zidovudine is an FDA-approved antiretroviral. Retrovir’s label includes oral capsules, oral solution, and intravenous administration. FDA-approved generic zidovudine products have used the ANDA pathway, relying on the established safety and efficacy of the reference drug. [1,2]

The regulatory status creates four main development routes:

Standard ANDA generic

This is the lowest-risk route for a conventional capsule or oral solution. The sponsor must demonstrate pharmaceutical equivalence, bioequivalence where required, quality, stability, and manufacturing compliance.

505(b)(2) reformulation

This route may apply to a novel liquid, modified-release product, new delivery system, or other formulation that relies partly on the established zidovudine safety profile. It can be attractive where a formulation benefit is clinically or operationally meaningful.

Fixed-dose combination

Zidovudine has been combined with other antiretrovirals, including lamivudine in combination products historically marketed as Combivir. Combination development faces additional analytical, stability, labeling, and bioequivalence requirements. The commercial opportunity is constrained by the shift toward newer, simpler antiretroviral regimens.

Hospital injectable product

A sterile generic injection can compete through procurement pricing and supply reliability. The market is limited, and manufacturing controls are more demanding than for capsules or oral liquids.

Which companies are challenging Retrovir exclusivity?

Zidovudine is challenged primarily by generic manufacturers rather than biosimilar developers. Companies active historically or currently in generic antiretroviral supply have included large multinational generic manufacturers and regional suppliers. The relevant competitive set depends on the specific dosage form and country.

For U.S. market analysis, the material competitors are manufacturers with approved or listed zidovudine products in the FDA’s Orange Book and Drugs@FDA databases. The strategic distinction is:

• capsule competitors compete mainly on price and supply;
• oral-solution competitors compete on palatability, dosing accuracy, and availability;
• injection competitors compete on hospital contracting, sterility, and supply continuity;
• combination-product sponsors compete on regimen convenience and procurement value.

No biosimilar risk applies because zidovudine is a chemically synthesized small molecule, not a biologic. [3]

What generic entry risks exist for a new Retrovir formulation?

A new zidovudine product faces low risk from the expired original patent estate but high risk from substitution and price erosion. The primary threats are:

1. rapid ANDA entry by established generic manufacturers;
2. therapeutic substitution into newer antiretroviral regimens;
3. hospital purchasing pressure;
4. limited willingness to pay for conventional excipient changes;
5. manufacturing failures involving oral-liquid stability or sterile filling;
6. low treatment volumes in markets where zidovudine has been displaced;
7. tender losses to suppliers with lower cost structures.

A formulation with no clinically visible benefit is likely to enter a commoditized market. A differentiated product needs a defensible value proposition, such as easier pediatric administration, lower dosing error, sugar-free composition, improved shelf stability, or reliable supply in low-resource settings.

What commercial opportunities exist for zidovudine excipient innovation?

Pediatric taste-masked oral solution

This is the clearest opportunity. A product that reduces bitterness, improves dosing accuracy, and remains stable without sucrose could target pediatric HIV programs, hospitals, and global-health procurement agencies.

Potential excipient approaches include:

• ion-exchange resin complexes;
• cyclodextrin inclusion complexes;
• polymeric taste-masking coatings;
• optimized sweetener and flavor systems;
• low-viscosity suspensions;
• preservative systems compatible with pediatric use.

The formulation must preserve zidovudine exposure and avoid excipient levels that create gastrointestinal intolerance.

Sugar-free oral liquid

A sugar-free formulation could target pediatric patients with diabetes risk, dental concerns, or dietary restrictions. The product should use an excipient system that controls osmolality and avoids excessive polyol exposure.

Ready-to-use hospital injection

A premixed or pharmacy-ready injection could reduce compounding steps and medication-preparation errors. The opportunity is strongest where hospital systems value ready-to-administer products and where supply disruptions affect standard vials.

Fixed-dose or co-packaged therapy

Zidovudine combinations may remain relevant in certain treatment protocols, prevention programs, or markets with established procurement systems. The commercial case is stronger for co-packaging or regimen-specific delivery than for a new zidovudine-only capsule.

Regional manufacturing and supply contracts

Zidovudine’s mature chemistry and established excipient profile make it suitable for regional production. Manufacturers can compete through:

• local API sourcing;
• shorter supply chains;
• public-sector tenders;
• pediatric product availability;
• dual-source manufacturing;
• lower minimum order quantities;
• packaging adapted to hot and humid climates.

The manufacturing barrier is lower for capsules than for sterile injections. Oral liquids require stronger microbiological and stability controls, while injections require validated aseptic processing and container-closure systems.

How does Retrovir compare with newer HIV medicines?

Factor	Zidovudine	Newer antiretrovirals
Patent barrier	Minimal for the core molecule	Often substantial
Generic price pressure	High	Variable
Clinical positioning	Narrower and often legacy-based	Generally preferred in modern guidelines
Pediatric liquid opportunity	Meaningful	Product-specific
Excipient differentiation	Feasible	Often protected by active product patents
Adherence advantage	Mostly formulation-dependent	Often driven by regimen simplicity
Biosimilar exposure	None	Relevant only to biologic HIV products
Commercial growth potential	Mature or declining	Higher for preferred modern regimens

Zidovudine’s commercial value is therefore concentrated in access markets, legacy protocols, pediatric formulations, and supply-constrained settings. It is unlikely to displace newer preferred antiretrovirals without a specific operational or clinical advantage.

What licensing deals and litigation affect Retrovir?

The original commercial history involved Burroughs Wellcome, later integrated into Glaxo Wellcome and GSK. HIV commercialization subsequently moved through GSK-related and ViiV Healthcare structures. The original brand relationship does not create current exclusivity over generic zidovudine.

No active, broad U.S. litigation barrier is central to ordinary zidovudine capsule or oral-solution entry. Current litigation risk would more likely arise from a newly patented formulation, device, manufacturing process, or combination product. A sponsor pursuing a differentiated product should expect Paragraph IV risk if it lists patents in the Orange Book and should design claims narrowly enough to withstand obviousness and enablement challenges.

Key Takeaways

• Retrovir is zidovudine, an FDA-approved small-molecule antiretroviral first approved in 1987.
• Its original composition and exclusivity rights have expired.
• Conventional capsule excipients offer little patent or pricing protection.
• Pediatric oral solution is the strongest excipient-led opportunity.
• Taste masking, sugar-free composition, dosing accuracy, and shelf stability are commercially relevant differentiators.
• Biosimilar competition does not apply.
• Generic competition is established, making price and supply reliability central.
• A 505(b)(2) strategy may fit a genuinely differentiated liquid, modified-release product, or delivery system.
• Ready-to-use injection and regional supply contracts are narrower but credible opportunities.
• Any new patent strategy should focus on measurable formulation performance rather than routine excipient substitution.

FAQs About Retrovir Excipient Strategy and Commercialization

Can a new flavor of Retrovir support a patent?

Usually not by itself. A patent position is stronger when the flavor system is part of a defined formulation that produces unexpected taste masking, stability, dose accuracy, or preservative performance.

Is a sugar-free zidovudine oral solution commercially attractive?

It can be attractive for pediatric, diabetic, dental-health, and specialized procurement markets. The product must control osmolality, gastrointestinal tolerability, chemical stability, and microbial preservation.

Does zidovudine have biosimilar competition?

No. Zidovudine is a chemically synthesized small molecule. Competitors use generic-drug pathways rather than biosimilar pathways.

Can a zidovudine formulation qualify for new FDA exclusivity?

Potentially, if it is a qualifying new formulation or indication and meets the statutory requirements. Ordinary generic capsules or a routine excipient substitution would not create meaningful new exclusivity.

What is the highest-value commercial segment for zidovudine?

A differentiated pediatric oral liquid is the strongest formulation opportunity. The value lies in administration, palatability, and access rather than in protection of the zidovudine molecule itself.

References

1. U.S. Food and Drug Administration. (1987). Retrovir (zidovudine) approval history and prescribing information. Drugs@FDA.

2. U.S. Food and Drug Administration. (2023). Retrovir (zidovudine) capsules, oral solution, and injection prescribing information. DailyMed.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.

4. World Health Organization. (2024). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring. Geneva: World Health Organization.